ArticleOPEN ACCESS

Erratum: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis (Neuro-Oncology Advances DOI: 10.1093/noajnl/vdaa082)

Neuro-Oncology Advances
DOI: 10.1093/noajnl/vdab095
1Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the originally published version of this manuscript, there was an error in co-author Mohammad Hassan Murad's name. The full name should read: "Mohammad Hassan Murad" instead of "Hassan M. Murad". This error has now been corrected online.

Cite

CITATION STYLE

APA

Alnahhas, I., Alsawas, M., Rayi, A., Palmer, J. D., Raval, R., Ong, S., … Puduvalli, V. (2021, January 1). Erratum: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis (Neuro-Oncology Advances DOI: 10.1093/noajnl/vdaa082). Neuro-Oncology Advances. Oxford University Press. https://doi.org/10.1093/noajnl/vdab095

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free